Uscom and US Koneksa Extend Technology Partnership
Uscom extends its ongoing partnership with digital biomarker leader Koneksa to develop and use Uscom’s digital patient-monitoring technology for spirometers in clinical trials. The agreement between the companies relates to the direct wireless integration of data from the Uscom’s SpiroSonic AIR device into Koneksa’s proprietary platform.
Summary:
The Uscom R&D team has developed new high-level spirometry algorithms and APPs to allow the breath-to-breath delivery of precise respiratory function data using the Uscom SpiroSonic AIR sensors. The SpiroSonic AIR technology utilises patent-protected digital ultrasonic technology for improved accuracy and stability compared to conventional spirometry, and has a unique design to enhance disinfection and simplify patient operation.
Koneksa, a New York based medical technology leader, specialises in the collection and analysis of biometric data for pharmaceutical and biotechnology trials and requires high-resolution physiologic monitoring. The company specialises in digital monitoring of multiple physiologic parameters such as actigraphy, gait and balance, and vital signs such as body temperature, SpO2, BP, respiration, and heart rate, and has been using Uscom SpiroSonic digital spirometers for a number of years.
The agreement between Uscom and Koneksa relates to the wireless integration of new functions from the Uscom’s SpiroSonic AIR device into Koneksa’s proprietary platform that will advance their leadership in the clinical trial space.
Commentary:
Uscom Executive Chairman, Professor Rob Phillips said “The Spirosonic AIR is the most advanced technology of its kind, and we are delighted to expand our partnership with Koneksa as they continue to grow their leadership in the pharmaceutical and biotechnology trial space. This growing collaboration is a recognition of its expanding role in mHealth monitoring of lung function and demonstrates the increasing importance of digital health monitoring. Koneksa requires the most sensitive front-end sensors to generate accurate data for their proprietary platform, and have been using Uscom devices in their studies for several years. This agreement establishes the pathway for our devices to become a standard lung-function testing device, and to be adopted in many pharmaceutical trials going forward. Lung function is a critical clinical measure in asthma, COPD, and COVID – both long and short – among other conditions.”